Pomerantz LLP is investigating argenx SE for potential securities fraud following the company's announcement to discontinue its Phase 3 UNITY study of efgartigimod SC in moderate-to-severe Sjögren's disease due to futility. The study's halt caused argenx's stock to drop nearly 12% on October 8, 2026. The investigation will determine if argenx and its officers engaged in unlawful business practices. Investors affected by the stock drop are encouraged to contact Pomerantz LLP for potential class action participation.
argenx SE is the subject of an investor investigation. For readers following the Health sector, here is Pluang's market snapshot as of Nov 04, 2026 05:12 WIB: Out of 150 priced US Health stocks, 89 rose and 58 fell. Notable movers include NBIX at USD 163.75 with a +12.66% change and 91% sell order activity, INO at USD 1.67 with -11.90% change and 53% sell orders, and IOVA at USD 8.86 with +10.47% change and 99% sell orders. Typical hold times range from 4 to 41 days.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
Anthropic announced FlashProve, an open-source system designed to cryptographically verify which AI model produced a given output. This system provides a mathematical proof that an answer truly comes from a claimed model, helping prevent impersonatio...
Pomerantz LLP is investigating Concentrix Corporation and its officers for potential securities fraud following the company's lowered revenue forecasts and a $1.05 billion goodwill impairment disclosed in 2026. The stock price dropped significantly a...
Stevanato Group's shares fell sharply after its third-quarter report showed an 8% revenue increase but lowered 2027 volume expectations for its GLP-1 portfolio. The company warned of slower growth than previously anticipated, prompting concerns among...
Pomerantz LLP is investigating Scholastic Corporation and its officers for potential securities fraud following the company's Q1 fiscal 2027 report. Scholastic reported an adjusted loss of $3.63 per share, missing estimates, and a 4% revenue decline ...
